Safety and Feasibility of 0.6 Mg/Kg Every 4 Weeks Dosing of Axatilimab in Patients Treated in the AGAVE-201 Study

Key Points

• Axatilimab dosing of 0.6 mg/kg every 4 weeks demonstrates safety and feasibility for patients.
• The most important metric revealed 0 adverse events during the treatment period.
• Assessment of axatilimab was conducted within the AGAVE-201 treatment framework.
• Findings support the application of systemic therapies with axatilimab in targeted patient populations.